Mono-centre, open-label study to investigate the multi-dose pharmacokinetics, efficacy and safety of Interferon alpha-2b Cream in women with a history of cytological diagnosed Pap IIID, with a confirmed histological diagnosis of CIN I or II, and of confirmed HPV+ status.

Trial Profile

Mono-centre, open-label study to investigate the multi-dose pharmacokinetics, efficacy and safety of Interferon alpha-2b Cream in women with a history of cytological diagnosed Pap IIID, with a confirmed histological diagnosis of CIN I or II, and of confirmed HPV+ status.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2012

At a glance

  • Drugs Interferon alpha-2b (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 21 Jul 2012 New source identified and integrated (European Clinical Trials Database).
    • 16 Sep 2011 Results will be presented at the Twenty Seventh International Papillomavirus Conference and Clinical Workshop, according to a Helix BioPharma media release.
    • 16 Sep 2011 Planned End Date changed to 1 Dec 2010, according to a Helix BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top